Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection

Vimalanand S. Prabhu, Oliver A. Cornely, Yoav Golan, Erik R. Dubberke, Sebastian M. Heimann, Mary E. Hanson, Jane Liao, Alison Pedley, Mary Beth Dorr, Stephen Marcella

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).

Original languageEnglish
Pages (from-to)1218-1221
Number of pages4
JournalClinical Infectious Diseases
Volume65
Issue number7
DOIs
StatePublished - Oct 1 2017

Keywords

  • C. difficile infection
  • bezlotoxumab
  • hospital readmissions
  • recurrence

Fingerprint Dive into the research topics of 'Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection'. Together they form a unique fingerprint.

  • Cite this

    Prabhu, V. S., Cornely, O. A., Golan, Y., Dubberke, E. R., Heimann, S. M., Hanson, M. E., Liao, J., Pedley, A., Dorr, M. B., & Marcella, S. (2017). Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection. Clinical Infectious Diseases, 65(7), 1218-1221. https://doi.org/10.1093/cid/cix523